Related Experiment Video
Updated: Jul 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic
Magdalena Koett1, Nastasiia Artamonova, Isabel Heidegger
1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Purpose Of Review:
The management of metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved into a complex landscape of doublet and triplet combination strategies. While treatment intensification was initially guided by clinical characteristics, growing insights into tumour biology are reshaping biomarker-driven decision-making algorithms. This review summarizes recent developments in mHSPC and incorporates new data presented at ESMO 2025 and ASCO GU 2026 within the current treatment landscape.
Recent Findings:
Phase III trials in the mHSPC presented at ESMO 2025 provide clinically relevant evidence supporting the earlier integration of biomarker-driven strategies, including poly(ADP-ribose) polymerase (PARP) inhibition in homologous recombination repair (HRR)-altered disease, protein kinase B (AKT) inhibition in PTEN-deficient tumours, and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy. These approaches consistently improve radiographic progression-free survival (rPFS); however, overall survival (OS) data remain immature, and quality-of-life benefits are variable. The optimal treatment sequencing as well as patient selection remain to be defined. In parallel, phase II studies, presented at ASCO GU 2026, are hypothesis-generating and highlight emerging concepts such as intensified androgen receptor blockade and biomarker-guided treatment de-escalation.
Summary:
Recent data reinforce the shift toward biomarker-driven management in mHSPC, but further maturation of clinical outcomes and careful balancing of efficacy and toxicity are required before broad clinical implementation.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
